Dexclamol

Antipsychotic compound From Wikipedia, the free encyclopedia

Dexclamol (AY 24169) was an investigational new drug developed by McKenna and Harrison, Ltd. that was evaluated as a antipsychotic.[1][2][3][4] It acts as a dopamine receptor antagonist.[1]

Other namesAY 24169
CAS Number
Quick facts Clinical data, Other names ...
Dexclamol
Clinical data
Other namesAY 24169
Identifiers
  • (1R,6R,8R)-6-propan-2-yl-3-azapentacyclo[11.8.1.03,8.09,22.016,21]docosa-9,11,13(22),16,18,20-hexaen-6-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H29NO
Molar mass347.502 g·mol−1
3D model (JSmol)
  • CC(C)[C@]1(CCN2C[C@@H]3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@H]2C1)O
  • InChI=1S/C24H29NO/c1-16(2)24(26)12-13-25-15-21-19-8-4-3-6-17(19)10-11-18-7-5-9-20(23(18)21)22(25)14-24/h3-9,16,21-22,26H,10-15H2,1-2H3/t21-,22-,24-/m1/s1
  • Key:UPMOVJBGNREKJV-CQOQZXRMSA-N
Close

See also

References

Related Articles

Wikiwand AI